MedTrace Logo

Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer

NCT00293540 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 249

Last updated 2016-07-27

Study results available
· View outcomes & findings →

Summary

This study will determine if hormone receptor positive premenopausal metastatic breast cancer patients who undergo removal of the ovaries in mid-luteal versus mid-follicular phase have a longer survival.

Conditions

Interventions

PROCEDURE

oophorectomy

Excision of an ovary

DRUG

Tamoxifen

20 mg orally every day

Sponsors & Collaborators

  • Breast Cancer Research Foundation

    collaborator OTHER

  • International Breast Cancer Research Foundation

    lead OTHER

Principal Investigators

  • Richard R. Love, MD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2014-02-28
Completion
2015-03-31

Countries

  • United States
  • Bangladesh
  • China
  • India
  • Indonesia
  • Malaysia
  • Morocco
  • Nigeria
  • Philippines
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00293540 on ClinicalTrials.gov